QIFENG
873169
LEETRO
430425
KSEC Intelligent Technology
301311
4
Guangdong Topstar Technology
300607
5
Hengerda New Materials
300946
CN Stock MarketDetailed Quotes
688606 Hangzhou Alltest Biotech
- 65.25
- +1.24+1.94%
Market Closed May 12 15:00 CST
5.17BMarket Cap16.22P/E (TTM)
66.41High64.00Low12.30KlotVolume64.74Open64.01Pre Close80.34MTurnover1.55%Turnover Ratio17.10P/E (Static)79.28MShares84.7252wk High1.31P/B5.17BFloat Cap43.7052wk Low76.81Limit Up79.28MShs Float148.07Historical High51.21Limit Down3.77%Amplitude43.09Historical Low3.00Dividend TTM65.30Avg Price5.89KlotAsk4.60%Div YieldTTM100Lot Size5.39KlotBid
Hangzhou Alltest Biotech Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 4.28%208.48M | 14.83%866.58M | 10.37%618.03M | 2.23%396.5M | -15.34%199.92M | -77.73%754.7M | -81.40%559.94M | -85.76%387.85M | -88.75%236.14M | 80.88%3.39B |
| Operating revenue | 4.28%208.48M | 14.83%866.58M | 10.37%618.03M | 2.23%396.5M | -15.34%199.92M | -77.73%754.7M | -81.40%559.94M | -85.76%387.85M | -88.75%236.14M | 80.88%3.39B |
| Total operating cost | -0.60%143.28M | -3.40%571.94M | -2.91%425.1M | -10.78%272.93M | -19.44%144.14M | -66.17%592.08M | -68.81%437.85M | -73.52%305.91M | -77.30%178.93M | 73.28%1.75B |
| Operating cost | -7.22%92.5M | -0.72%383.74M | -6.25%273.43M | -13.86%178.39M | -10.73%99.7M | -71.53%386.54M | -73.04%291.66M | -77.73%207.1M | -83.44%111.69M | 61.64%1.36B |
| Operating tax surcharges | 43.13%2.93M | 35.93%9.57M | 28.96%4.77M | 37.89%3.58M | 28.80%2.05M | -74.71%7.04M | -81.79%3.7M | -81.94%2.6M | -4.97%1.59M | 180.28%27.82M |
| Operating expense | 29.55%14.01M | -20.06%55.39M | -11.72%41.89M | -7.95%30.05M | -35.15%10.81M | -53.91%69.29M | -64.18%47.45M | -68.30%32.64M | -60.92%16.67M | 202.12%150.34M |
| Administration expense | 11.52%15.05M | -2.62%64.84M | -5.81%45.64M | -12.56%30.14M | -25.74%13.49M | -14.70%66.59M | -25.79%48.45M | -11.59%34.46M | -10.72%18.17M | 138.61%78.06M |
| Financial expense | 53.42%-2.37M | 36.06%-37.43M | 71.87%-12.13M | 50.00%-18.39M | 4.59%-5.08M | 17.47%-58.54M | 22.50%-43.11M | -19.01%-36.77M | -344.00%-5.32M | -300.76%-70.93M |
| -Interest expense (Financial expense) | -57.83%55.9K | -71.53%415.35K | -68.65%366.18K | -68.71%260.84K | -70.04%132.56K | -32.80%1.46M | -35.03%1.17M | -32.15%833.66K | -41.46%442.38K | 224.69%2.17M |
| -Interest Income (Financial expense) | 57.67%-2.27M | 26.56%-33.47M | 39.44%-17.86M | 19.82%-17.48M | 36.50%-5.37M | -6.26%-45.57M | 9.24%-29.49M | -37.90%-21.8M | -104.40%-8.45M | -13.14%-42.89M |
| Research and development | -8.66%21.15M | -20.92%95.82M | -20.28%71.5M | -25.38%49.16M | -35.89%23.16M | -41.55%121.17M | -43.72%89.69M | -34.08%65.88M | -22.89%36.12M | 117.16%207.3M |
| Credit Impairment Loss | 60.42%-4.5M | 30.61%-7.79M | 1.21%-13.94M | -13.89%-12.26M | -45.58%-11.37M | -102.06%-11.23M | -103.75%-14.11M | -72.34%-10.77M | -85.30%-7.81M | 17.91%-5.56M |
| Asset Impairment Loss | 98.16%-100.1K | -261.96%-9.07M | -793.52%-7.31M | -275.45%-8.39M | 68.09%-5.44M | 102.00%5.6M | 101.48%1.05M | 106.72%4.78M | 76.00%-17.06M | -7,016.09%-280.06M |
| Other net revenue | ||||||||||
| Fair value change income | -37.53%2.1M | 8.82%35.55M | 354.49%22.55M | 797.97%12.66M | -64.70%3.36M | 314.66%32.67M | -83.25%4.96M | -90.61%1.41M | --9.53M | -171.36%-15.22M |
| Invest income | -87.69%517.48K | 41.23%12.19M | 82.70%11.59M | 46.95%9.21M | -9.77%4.2M | -64.20%8.63M | -56.10%6.34M | -49.29%6.26M | 61.98%4.66M | 246.83%24.12M |
| -Including: Investment income associates | ---82.47K | ---474.89K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | ---- | 392.14%1.22M | 750.33%3.48M | 724.52%3.34M | 99.28%-6.08K | -178.63%-419.22K | -3,438.20%-535.17K | -489,844.80%-535.17K | -774,917.52%-846.55K | 1,004.34%533.17K |
| Other revenue | 70.35%1.36M | 36.88%18.77M | 88.04%17.49M | 74.27%13.92M | 38.25%796.95K | -56.82%13.71M | -64.22%9.3M | -56.58%7.99M | -85.47%576.47K | 99.67%31.75M |
| Operating profit | 36.44%64.57M | 63.30%345.52M | 75.66%226.78M | 55.97%142.05M | 2.32%47.33M | -84.82%211.58M | -91.92%129.1M | -94.07%91.08M | -96.28%46.25M | 55.43%1.39B |
| Add:Non operating Income | ---- | 13,131.01%3.19M | 1,186.68%179.81K | 1,186.18%179.74K | 11,774.39%100K | -80.76%24.08K | -98.54%13.97K | -95.06%13.97K | -99.47%842.15 | 114.87%125.17K |
| Less:Non operating expense | -79.77%54.96K | -93.01%990.91K | -74.25%3.64M | -77.72%3.08M | 35.77%271.7K | 13.29%14.17M | 45.09%14.15M | 48.33%13.83M | -96.34%200.11K | 879.44%12.51M |
| Total profit | 36.82%64.52M | 76.11%347.71M | 94.25%223.32M | 80.10%139.15M | 2.39%47.16M | -85.71%197.44M | -92.77%114.96M | -94.94%77.26M | -96.28%46.06M | 54.26%1.38B |
| Less:Income tax cost | 32.94%3.34M | 161.12%44.8M | 87.89%25.77M | 142.62%15.61M | -56.06%2.51M | -91.25%17.16M | -94.01%13.72M | -97.14%6.44M | -96.95%5.72M | 50.94%195.99M |
| Net profit | 37.04%61.18M | 68.02%302.91M | 95.11%197.55M | 74.42%123.53M | 10.68%44.64M | -84.79%180.28M | -92.56%101.25M | -94.56%70.83M | -96.16%40.34M | 54.82%1.19B |
| Net profit from continuing operation | 37.04%61.18M | 68.02%302.91M | 95.11%197.55M | 74.42%123.53M | 10.68%44.64M | -84.79%180.28M | -92.56%101.25M | -94.56%70.83M | -96.16%40.34M | 54.82%1.19B |
| Less:Minority Profit | 74.22%-37.27K | 248.14%437.87K | 105.87%18.76K | 2.86%-344.83K | 26.37%-144.58K | -154.94%-295.58K | -283.53%-319.37K | -506.30%-355K | -120.88%-196.37K | --538.05K |
| Net profit of parent company owners | 36.68%61.22M | 67.50%302.47M | 94.48%197.53M | 74.03%123.88M | 10.50%44.79M | -84.76%180.58M | -92.53%101.57M | -94.54%71.18M | -96.14%40.53M | 54.75%1.18B |
| Earning per share | ||||||||||
| Basic earning per share | 37.50%0.77 | 67.54%3.82 | 94.53%2.49 | 73.33%1.56 | 9.80%0.56 | -84.75%2.28 | -92.54%1.28 | -94.52%0.9 | -97.38%0.51 | -1.32%14.95 |
| Diluted earning per share | 37.50%0.77 | 67.54%3.82 | 94.53%2.49 | 73.33%1.56 | 9.80%0.56 | -84.75%2.28 | --1.28 | --0.9 | --0.51 | --14.95 |
| Other composite income | -282.80%-276.67K | -25.57%1.76M | -138.06%-1.48M | -86.37%648.53K | 153.93%151.35K | -91.58%2.37M | -86.50%3.88M | -66.90%4.76M | -410.05%-280.66K | 21,705.78%28.12M |
| Other composite income of parent company owners | -289.59%-274.16K | -26.12%1.75M | -138.09%-1.48M | -86.58%637.99K | 142.57%144.61K | -91.60%2.36M | -86.52%3.88M | -66.93%4.75M | -464.00%-339.7K | 21,710.09%28.13M |
| Other composite income of minority owners | -137.19%-2.51K | 262.01%16.27K | -89.24%285.66 | 149.32%10.55K | -88.58%6.74K | 180.83%4.5K | 119.25%2.65K | --4.23K | 2,205.68%59.05K | ---5.56K |
| Total composite income | 35.96%60.9M | 66.81%304.67M | 86.50%196.07M | 64.30%124.18M | 11.83%44.8M | -84.95%182.65M | -92.43%105.13M | -94.26%75.59M | -96.18%40.06M | 58.47%1.21B |
| Total composite income of parent company owners | 35.63%60.94M | 66.29%304.22M | 85.92%196.05M | 63.98%124.52M | 11.79%44.93M | -84.92%182.94M | -92.41%105.45M | -94.23%75.94M | -96.17%40.19M | 58.40%1.21B |
| Total composite income of minority owners | 71.14%-39.78K | 256.02%454.15K | 106.01%19.04K | 4.70%-334.28K | -0.37%-137.84K | -154.67%-291.09K | -297.67%-316.72K | -501.46%-350.77K | -49.74%-137.33K | --532.49K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.